Indeed, anastrozole was administered when the circulating levels of IGF-1 were high due to the interruption of pegvisomant treatment, while the shift to tamoxifen coincided with re-starting pegvisomant and the subsequent metabolic control of acromegaly. Here, IGF1 is linked to acromegaly.